Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fabric.AI, Inc.FABC · Entity 7732 | Director · Chief Executive Officer | June 18, 2026 | August 14, 2026 |
| NATIONAL HOLDINGS CORPNHLD · Entity 142239 | Director | September 12, 2016 | September 13, 2016 |
| Neurotrope, Inc.NTRP · Entity 144906 | Director | December 01, 2020 | December 03, 2020 |
| Petros Pharmaceuticals, Inc.PTPI · Entity 8730 | Director | June 05, 2026 | June 05, 2026 |
| PharmaCyte Biotech, Inc.PMCB · Entity 8256 | Director · CEO and President | January 05, 2026 | January 07, 2026 |
| Protagenic Therapeutics, Inc.\newPTIX · Entity 8496 | Director | February 21, 2020 | February 27, 2020 |
| Q/C TECHNOLOGIES, INC.QCLS · Entity 7735 | Director · Executive Chairman | July 10, 2026 | October 03, 2026 |
| TAO Synergies Inc.TAOX · Entity 7482 | Director · Executive Chairman | May 18, 2026 | May 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fabric.AI, Inc.
Report date June 18, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 280,757 |
Ending reported balance
After 2026-06-30 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-06-18 · Grant · Acquired 358,565 · Balance 370,397 F1: Represents a grant of restricted shares (the "Stock Award") of common stock, par value $0.0001 per share ("Common Stock"), of the Issuer granted to the Reporting Person under the Fabric.AI, Inc. Long-Term Incentive Plan (as amended, the "Plan"). The Stock Award vests as follows: (i) 25% vested on June 18, 2026, (ii) 25% vested on June 30, 2026, (iii) 25% will vest on September 30, 2026, and (iv) 25% will vest on December 31, 2026. Row 2 · 2026-06-18 · Tax withholding · Disposed 44,820 · Balance 325,577 Row 3 · 2026-06-30 · Tax withholding · Disposed 44,820 · Balance 280,757 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted shares (the "Stock Award") of common stock, par value $0.0001 per share ("Common Stock"), of the Issuer granted to the Reporting Person under the Fabric.AI, Inc. Long-Term Incentive Plan (as amended, the "Plan"). The Stock Award vests as follows: (i) 25% vested on June 18, 2026, (ii) 25% vested on June 30, 2026, (iii) 25% will vest on September 30, 2026, and (iv) 25% will vest on December 31, 2026.
NATIONAL HOLDINGS CORP
Report date September 12, 2016 · Filed September 13, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.02 per shareSEC Table I · non-derivative | IndirectSee Footnote | 414,323 |
Reported balance
After 2016-09-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2016-09-12 · Other · Acquired 414,323 · Balance 414,323 F1: Securities validly tendered by Iroquois Master Fund (the "Fund") in the tender offer by FBIO Acquisition, Inc., a wholly-owned subsidiary of Fortress Biotech, Inc. Mr. Silverman disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Securities validly tendered by Iroquois Master Fund (the "Fund") in the tender offer by FBIO Acquisition, Inc., a wholly-owned subsidiary of Fortress Biotech, Inc. Mr. Silverman disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Neurotrope, Inc.
Report date December 01, 2020 · Filed December 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 1
1 source rowRow 1 · 2020-12-01 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.20 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-01 · Disposition to issuer · Disposed 9,375 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-01 · Disposition to issuer · Disposed 124,275 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.10 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.62 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-12-01 · Disposition to issuer · Disposed 167,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.91 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-12-01 · Disposition to issuer · Disposed 150,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.06 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-12-01 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held.
F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Petros Pharmaceuticals, Inc.
Report date June 05, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,790,450 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 4,375,000 · Balance 8,790,450 F1: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.
PharmaCyte Biotech, Inc.
Report date January 05, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 416,250 |
Ending reported balance
After 2026-01-07 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-01-05 · Purchase · Acquired 30,000 · Balance 346,250 Row 2 · 2026-01-06 · Purchase · Acquired 30,000 · Balance 376,250 Row 3 · 2026-01-07 · Purchase · Acquired 40,000 · Balance 416,250 |
| Common StockSEC Table I · non-derivative | IndirectJNS Holdings Group LLC | 50,000 |
Reported balance
Holding disclosure · report date 2026-01-05 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 50,000 |
Protagenic Therapeutics, Inc.\new
Report date February 21, 2020 · Filed February 27, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| PTIX Common stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2030-02-21 | Direct | 120,000 |
Reported balance
After 2020-02-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-21 · Grant · Acquired 120,000 · Balance 120,000 |
Q/C TECHNOLOGIES, INC.
Report date July 10, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 210,845 |
Ending reported balance
After 2026-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-10 · Grant · Acquired 16,620 · Balance 133,455 F1: Represents a grant of Restricted Stock. The Restricted Stock was granted to the Reporting Person pursuant to an executive compensation agreement, dated April 13, 2026, by and between the Issuer and the Reporting Person (the "Compensation Agreement") providing for quarterly grants equal to $60,000. The Restricted Stock vested pursuant to the terms of the Compensation Agreement. Row 2 · 2026-10-01 · Grant · Acquired 77,390 · Balance 210,845 F2: Represents a grant of Restricted Stock. The Restricted Stock was granted to the Reporting Person pursuant to the Compensation Agreement. The Restricted Stock vested pursuant to the terms of the Compensation Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of Restricted Stock. The Restricted Stock was granted to the Reporting Person pursuant to an executive compensation agreement, dated April 13, 2026, by and between the Issuer and the Reporting Person (the "Compensation Agreement") providing for quarterly grants equal to $60,000. The Restricted Stock vested pursuant to the terms of the Compensation Agreement.
F2: Represents a grant of Restricted Stock. The Restricted Stock was granted to the Reporting Person pursuant to the Compensation Agreement. The Restricted Stock vested pursuant to the terms of the Compensation Agreement.
TAO Synergies Inc.
Report date May 18, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2036-05-18 | Direct | 200,000 |
Reported balance
After 2026-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-18 · Grant · Acquired 200,000 · Balance 200,000 F1: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
FEMASYS INC
Report date March 17, 2026 · Filed March 18, 2026
Section 16 reporting ended · disclosed 2026-03-18. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Marker Therapeutics, Inc.
Report date October 16, 2018 · Filed October 17, 2018
Section 16 reporting ended · disclosed 2018-10-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,221 |
Reported balance
After 2018-10-16 transaction · row 1
1 source rowRow 1 · 2018-10-16 · Grant · Acquired 4,106 · Balance 17,221 F1: Represents the pro-rated portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $7.74 per share, on the day immediately preceding the date of the Company's 2018 annual meeting. |
| Common StockSEC Table I · non-derivative | IndirectBy JNS Holdings Group LLC | 153,333 |
Reported balance
Holding disclosure · report date 2018-10-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 153,333 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the pro-rated portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $7.74 per share, on the day immediately preceding the date of the Company's 2018 annual meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2019 Filed Aug 30, 2019 01:44 UTC | Fabric.AI, Inc. DCAR · Entity 7732 | Tax withholdingCommon Stock | 14,972 | $0.78 | $11,678.16 |
DisclosureSEC source: 0001654954-19-010165 · section16.xml · nonDerivative · entry 2 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,915 Read SEC document |
| August 27, 2019 Filed Aug 30, 2019 01:44 UTC | Fabric.AI, Inc. DCAR · Entity 7732 | GrantCommon Stock | 75,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-19-010165 · section16.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,887 F1 · date: One-half of the shares vest on August 27, 2019, with the remaining shares vesting in two equal installments on October 31, 2019 and January 31, 2020. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 21:15 UTC | Q/C TECHNOLOGIES, INC. AKER · Entity 7735 | GrantRestricted Stock Units · Derivative | 124,827 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-004748 · ownership.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,827 Underlying: Common Stock · 124,827 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). The Company may also elect to settle the vested RSUs for cash at its discretion. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). The Company may also elect to settle the vested RSUs for cash at its discretion. F2 · derivative.exercise_date: Reporting Person was granted 124,827 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), each of which shall vest on January 1, 2020; provided that the RSUs shall vest immediately upon a Change in Control. All capitalized but undefined terms have the meanings ascribed thereto by the Plan. F2 · derivative.expiration_date: Reporting Person was granted 124,827 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), each of which shall vest on January 1, 2020; provided that the RSUs shall vest immediately upon a Change in Control. All capitalized but undefined terms have the meanings ascribed thereto by the Plan. Read SEC document |
| March 15, 2019 Filed Apr 15, 2019 17:00 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.06 | $0.00 |
DisclosureSEC source: 0001144204-19-019712 · tv518875_4.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-03-15 F1 · security: The stock option award was made in connection with the Issuer's annual equity grants to non-employee directors pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. Read SEC document |
| February 11, 2019 Filed Feb 22, 2019 22:04 UTC | Fabric.AI, Inc. DCAR · Entity 7732 | OtherWarrant to purchase Common Stock · Derivative | 1,161 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001654954-19-001907 · section16.xml · derivative · entry 4 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,161 Underlying: Common Stock · 1,161 shares Expires 2024-12-14 F1 · kind: Liquidating distribution from American Capital Management, LLC. F2 · ownership.nature: By JNS Holding Group LLC. Read SEC document |
| February 11, 2019 Filed Feb 22, 2019 22:04 UTC | Fabric.AI, Inc. DCAR · Entity 7732 | OtherWarrant to purchase Common Stock · Derivative | 1,716 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001654954-19-001907 · section16.xml · derivative · entry 3 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,716 Underlying: Common Stock · 1,716 shares Expires 2024-12-08 F1 · kind: Liquidating distribution from American Capital Management, LLC. F2 · ownership.nature: By JNS Holding Group LLC. Read SEC document |
| February 11, 2019 Filed Feb 22, 2019 22:04 UTC | Fabric.AI, Inc. DCAR · Entity 7732 | OtherWarrant to purchase Common Stock · Derivative | 2,223 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0001654954-19-001907 · section16.xml · derivative · entry 2 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,223 Underlying: Common Stock · 2,223 shares Expires 2024-12-07 F1 · kind: Liquidating distribution from American Capital Management, LLC. F2 · ownership.nature: By JNS Holding Group LLC. Read SEC document |
| February 11, 2019 Filed Feb 22, 2019 22:04 UTC | Fabric.AI, Inc. DCAR · Entity 7732 | OtherWarrant to purchase Common Stock · Derivative | 1,667 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001654954-19-001907 · section16.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,667 Underlying: Common Stock · 1,667 shares Expires 2024-12-06 F1 · kind: Liquidating distribution from American Capital Management, LLC. F2 · ownership.nature: By JNS Holding Group LLC. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 18:02 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0001144204-19-002684 · tv511524_4.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-01-22 F1 · derivative.exercise_date: The stock option award was made pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. The stock options shall vest according to the following schedule: 50% vest on the date of grant, with the remaining stock options vesting in equal quarterly installments over a two-year period following the date of grant. Read SEC document |
| October 16, 2018 Filed Oct 17, 2018 12:54 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | GrantCommon Stock | 4,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-054109 · tv504936_4.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,221 F1 · shares: Represents the pro-rated portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $7.74 per share, on the day immediately preceding the date of the Company's 2018 annual meeting. Read SEC document |
| June 26, 2018 Filed Jun 27, 2018 01:00 UTC | Fabric.AI, Inc. DCAR · Entity 7732 | PurchaseCommon Stock | 5,000 | $1.29 | $6,437.50 |
DisclosureSEC source: 0001144204-18-035923 · tv497228_4.xml · nonDerivative · entry 3 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JNS Holdings Group LLC Disclosed balance after: 35,109 Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 01:00 UTC | Fabric.AI, Inc. DCAR · Entity 7732 | PurchaseCommon Stock | 11,700 | $1.25 | $14,573.52 |
DisclosureSEC source: 0001144204-18-035923 · tv497228_4.xml · nonDerivative · entry 2 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JNS Holdings Group LLC Disclosed balance after: 30,109 Read SEC document |
| June 22, 2018 Filed Jun 27, 2018 01:00 UTC | Fabric.AI, Inc. DCAR · Entity 7732 | PurchaseCommon Stock | 13,300 | $1.27 | $16,893.66 |
DisclosureSEC source: 0001144204-18-035923 · tv497228_4.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JNS Holdings Group LLC Disclosed balance after: 18,409 Read SEC document |
| May 14, 2018 Filed Dec 3, 2018 16:27 UTC | Fabric.AI, Inc. DCAR · Entity 7732 | GrantStock option (right to buy) · Derivative | 18,282 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001654954-18-013485 · section16.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,282 Underlying: Common stock · 18,282 shares Expires 2028-05-14 F1 · shares: The stock options were granted in connection with the reporting person's service as a director and were subject to stockholder approval of an amendment to the Issuer's Amended and Restated 2014 Equity Incentive Plan under which the option was granted, which approval was received on November 15, 2018. F2 · derivative.exercise_date: The options vest in quarterly installments in arrears over a one year period. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 17:01 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.91 | $0.00 |
DisclosureSEC source: 0001144204-18-014959 · tv488494_form4.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-03-13 F1 · shares: Represents the annual option grant to each of the Issuer's non-employee directors on the fifth business day after the Issuer's filing of its Annual Report on Form 10-K pursuant to the Issuer's Nonemployee Director Compensation Policy. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:54 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | OtherSeries F Warrants · Derivative | 49,167 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001144204-18-012627 · tv487621_4.xml · derivative · entry 7 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JNS Holdings Group LLC Disclosed balance after: 49,167 Underlying: Common Stock · 49,167 shares Expires 2021-08-11 F1 · kind: Securities received from pro rata distribution in connection with the dissolution of American Capital Management LLC, of which the reporting person was a non-managing member. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:54 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | OtherSeries E-1 Warrants · Derivative | 31,093 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001144204-18-012627 · tv487621_4.xml · derivative · entry 6 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JNS Holdings Group LLC Disclosed balance after: 31,093 Underlying: Common Stock · 31,093 shares Expires 2020-10-08 F1 · kind: Securities received from pro rata distribution in connection with the dissolution of American Capital Management LLC, of which the reporting person was a non-managing member. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:54 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | OtherSeries E Warrants · Derivative | 10,574 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001144204-18-012627 · tv487621_4.xml · derivative · entry 5 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JNS Holdings Group LLC Disclosed balance after: 10,574 Underlying: Common Stock · 10,574 shares Expires 2020-10-08 F1 · kind: Securities received from pro rata distribution in connection with the dissolution of American Capital Management LLC, of which the reporting person was a non-managing member. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:54 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | OtherSeries D Warrants · Derivative | 41,667 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001144204-18-012627 · tv487621_4.xml · derivative · entry 4 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JNS Holdings Group LLC Disclosed balance after: 41,667 Underlying: Common Stock · 41,667 shares Expires 2020-01-16 F1 · kind: Securities received from pro rata distribution in connection with the dissolution of American Capital Management LLC, of which the reporting person was a non-managing member. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:54 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | OtherSeries C Warrants · Derivative | 44,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001144204-18-012627 · tv487621_4.xml · derivative · entry 3 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JNS Holdings Group LLC Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2020-01-16 F1 · kind: Securities received from pro rata distribution in connection with the dissolution of American Capital Management LLC, of which the reporting person was a non-managing member. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:54 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | OtherSeries A Warrants · Derivative | 41,667 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001144204-18-012627 · tv487621_4.xml · derivative · entry 2 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JNS Holdings Group LLC Disclosed balance after: 41,667 Underlying: Common Stock · 41,667 shares Expires 2020-01-16 F1 · kind: Securities received from pro rata distribution in connection with the dissolution of American Capital Management LLC, of which the reporting person was a non-managing member. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:54 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | OtherCommon Stock | 153,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-012627 · tv487621_4.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JNS Holdings Group LLC Disclosed balance after: 153,333 F1 · kind: Securities received from pro rata distribution in connection with the dissolution of American Capital Management LLC, of which the reporting person was a non-managing member. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:53 UTC | Fabric.AI, Inc. DCAR · Entity 7732 | OtherWarrants · Derivative | 1,716 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001144204-18-012626 · tv487620_4.xml · derivative · entry 5 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JNS Holdings Group LLC Disclosed balance after: 1,716 Underlying: Common Stock · 1,716 shares Expires 2024-12-08 F1 · kind: Securities received from pro rata distribution in connection with the dissolution of American Capital Management LLC, of which the reporting person was a non-managing member. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:53 UTC | Fabric.AI, Inc. DCAR · Entity 7732 | OtherWarrants · Derivative | 2,222 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0001144204-18-012626 · tv487620_4.xml · derivative · entry 4 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JNS Holdings Group LLC Disclosed balance after: 2,222 Underlying: Common Stock · 2,222 shares Expires 2024-12-07 F1 · kind: Securities received from pro rata distribution in connection with the dissolution of American Capital Management LLC, of which the reporting person was a non-managing member. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:53 UTC | Fabric.AI, Inc. DCAR · Entity 7732 | OtherWarrants · Derivative | 1,161 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001144204-18-012626 · tv487620_4.xml · derivative · entry 3 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JNS Holdings Group LLC Disclosed balance after: 1,161 Underlying: Common Stock · 1,161 shares Expires 2024-12-12 F1 · kind: Securities received from pro rata distribution in connection with the dissolution of American Capital Management LLC, of which the reporting person was a non-managing member. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:53 UTC | Fabric.AI, Inc. DCAR · Entity 7732 | OtherWarrants · Derivative | 1,667 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001144204-18-012626 · tv487620_4.xml · derivative · entry 2 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JNS Holdings Group LLC Disclosed balance after: 1,667 Underlying: Common Stock · 1,667 shares Expires 2024-12-06 F1 · kind: Securities received from pro rata distribution in connection with the dissolution of American Capital Management LLC, of which the reporting person was a non-managing member. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:53 UTC | Fabric.AI, Inc. DCAR · Entity 7732 | OtherCommon Stock | 5,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-012626 · tv487620_4.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JNS Holdings Group LLC Disclosed balance after: 5,109 F1 · kind: Securities received from pro rata distribution in connection with the dissolution of American Capital Management LLC, of which the reporting person was a non-managing member. F2 · balance_after: Mr. Silverman no longer has beneficial ownership of the shares previously reported as indirectly owned on his Form 3. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 18:18 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | GrantNon-Qualified Stock Options (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001437749-17-017234 · rdgdoc.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Protagenic Therapeutics, Inc. Common Stock · 45,000 shares Expires 2027-10-16 F1 · derivative.exercise_date: Vesting in equal installments over 18 months Read SEC document |
| August 29, 2017 Filed Aug 30, 2017 20:05 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | GrantCommon Stock | 13,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-045909 · v474359_4.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,115 F1 · shares: Represents the portion of the annual retainer for each non-employee director payable in immediately vested restricted, common stock under the Company's 2014 Omnibus Stock Ownership Plan and based on the closing price of $3.05 per share, on the day immediately preceding the date of the Company's 2017 annual meeting. Read SEC document |
| April 28, 2017 Filed May 2, 2017 20:33 UTC | Fabric.AI, Inc. WPCS · Entity 7732 | GrantStock Option (right to purchase) · Derivative | 50,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001144204-17-023965 · v465757_4.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-04-28 F1 · derivative.exercise_date: The options were granted under the WPCS International Incorporated 2014 Equity Incentive Plan. The 50,000 options vested immediately upon granting,. In addition, all 50,000 options owned by the Reporting Person are subject to a lock up agreement which will expire on the earlier of December 30, 2017 and a change in control of the Issuer. Read SEC document |
| April 11, 2017 Filed Apr 13, 2017 21:46 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 167,000 | $0.00 Strike: $19.62 | $0.00 |
DisclosureSEC source: 0001144204-17-020448 · v464204_4.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,000 Underlying: Common Stock · 167,000 shares Expires 2027-04-11 F1 · security: Such option grant is subject to stockholder approval of the Issuer's 2017 Equity Incentive Plan under which the option was granted. F2 · derivative.exercise_date: The stock options vest in equal quarterly installments over a three-year period. Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 21:53 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.10 | $0.00 |
DisclosureSEC source: 0001144204-17-015934 · v462247_4.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-03-17 F1 · security: Represents the annual option grant to each of the Issuer's non-employee directors on the fifth business day after the Issuer's filing of its Annual Report on Form 10-K pursuant to the Issuer's Nonemployee Director Compensation Policy. Such option grant is subject to stockholder approval of the Issuer's 2017 Equity Incentive Plan under which the option was granted. Read SEC document |
| November 28, 2016 Filed Nov 30, 2016 21:49 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | GrantEmployee Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001524858-16-000009 · primary_doc.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2026-11-27 F1 · security: Represents options granted in connection with appointment as a director of the Company on November 28, 2016 under the Company's 2014 Omnibus Stock Ownership Plan. These shares shall vest in monthly installments over a two year period. The option exercise price is the closing price on the date of the grant, November 28, 2016. F1 · derivative.exercise_date: Represents options granted in connection with appointment as a director of the Company on November 28, 2016 under the Company's 2014 Omnibus Stock Ownership Plan. These shares shall vest in monthly installments over a two year period. The option exercise price is the closing price on the date of the grant, November 28, 2016. Read SEC document |
| November 21, 2016 Filed Nov 23, 2016 17:02 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option · Derivative | 3,976,767 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001144204-16-136406 · v453762_4.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,976,767 Underlying: Common Stock · 3,976,767 shares Expires 2026-11-21 F2 · price: These options were granted in connection with the Issuer's grant to certain officers, directors and employees following the final closing of a private placement on November 21, 2016. F1 · derivative.exercise_date: One half of the stock options vest immediately upon grant and the remaining one half vest in equal daily installments over a four-year period beginning on the date of grant. Read SEC document |
| September 12, 2016 Filed Sep 13, 2016 16:32 UTC | NATIONAL HOLDINGS CORP NHLD · Entity 142239 | OtherCommon Stock, par value $0.02 per share | 414,323 | $3.25 | $1,346,549.75 |
DisclosureSEC source: 0001437749-16-038632 · rdgdoc.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 414,323 F1 · ownership.nature: Securities validly tendered by Iroquois Master Fund (the "Fund") in the tender offer by FBIO Acquisition, Inc., a wholly-owned subsidiary of Fortress Biotech, Inc. Mr. Silverman disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.